Ignite Creation Date:
2024-05-05 @ 6:47 PM
Last Modification Date:
2024-10-26 @ 9:36 AM
Study NCT ID:
NCT00540072
Status:
COMPLETED
Last Update Posted:
2019-11-14
First Post:
2007-10-04
Brief Title:
Study of Cidecin Daptomycin to Rocephin Ceftriaxone in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S Pneumoniae
Sponsor:
Organization:
Cubist Pharmaceuticals LLC a subsidiary of Merck Co Inc Rahway New Jersey USA
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
None
Enrollment Type:
None
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
Observational Models:
Time Perspective List:
Who Masked List: